Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5270371
Max Phase: Preclinical
Molecular Formula: C41H77N7O7S
Molecular Weight: 812.18
Associated Items:
ID: ALA5270371
Max Phase: Preclinical
Molecular Formula: C41H77N7O7S
Molecular Weight: 812.18
Associated Items:
Canonical SMILES: CCCCCCCCCCCCCC(=S)NCCCC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC(C)C)C(=O)N[C@H](C(=O)O)[C@@H](C)O
Standard InChI: InChI=1S/C41H77N7O7S/c1-5-6-7-8-9-10-11-12-13-14-15-24-35(56)44-26-19-17-22-33(38(51)47-36(30(4)49)41(54)55)45-37(50)32(21-16-18-25-42)46-39(52)34-23-20-27-48(34)40(53)31(43)28-29(2)3/h29-34,36,49H,5-28,42-43H2,1-4H3,(H,44,56)(H,45,50)(H,46,52)(H,47,51)(H,54,55)/t30-,31+,32+,33+,34+,36+/m1/s1
Standard InChI Key: VKZVLYJRBPURRQ-GBWMPDFWSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 812.18 | Molecular Weight (Monoisotopic): 811.5605 | AlogP: 4.19 | #Rotatable Bonds: 32 |
Polar Surface Area: 229.21 | Molecular Species: ZWITTERION | HBA: 9 | HBD: 8 |
#RO5 Violations: 2 | HBA (Lipinski): 14 | HBD (Lipinski): 10 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 3.76 | CX Basic pKa: 13.43 | CX LogP: 1.87 | CX LogD: 1.15 |
Aromatic Rings: 0 | Heavy Atoms: 56 | QED Weighted: 0.04 | Np Likeness Score: 0.08 |
1. Fiorentino F, Mai A, Rotili D.. (2021) Emerging Therapeutic Potential of SIRT6 Modulators., 64 (14.0): [PMID:34213345] [10.1021/acs.jmedchem.1c00601] |
Source(1):